Aim:Breast cancer (BC) is by far seen as the most common malignancy globally,
with 2.261 million patients newly diagnosed, accounting for 11.7% of all cancer patients, according
to the Global Cancer Statistics Report (2020). The luminal A subtype accounts for at
least half of all BC diagnoses. According to TCM theory, Bushen Huoxue Decoction (BSHXD)
is a prescription used for cancer treatment that may influence luminal A subtype breast cancer
(LASBC).Objectives:To analyze the clinical efficacy and underlying mechanisms of BSHXD in LASBC.Materials and Methods:Network pharmacology and in vitro experiments were utilized to foresee
the underlying mechanism of BSHXD for LASBC.Results:According to the bioinformatics analysis, BSHXD induced several proliferation and
apoptosis processes against LASBC, and the presumed targets of active components in BSHXD
were mainly enriched in the HIF-1 and PI3K/AKT pathways. Flow cytometry assay and western
blotting results revealed that the rate of apoptosis enhanced in a dose-dependent manner with
BSHXD concentration increasing, respectively. BSHXD notably downregulated the expressions
of HIF-1α, P-PI3K, PI3K, P-AKT and AKT proteins. However, adding an HIF-1α agonist restored
those protein levels.Conclusion:The study proved that the mechanism of BSHXD in LASBC may be connected to
suppressing proliferation by inhibiting the activity of the HIF-1α/PI3K/AKT signaling pathway
and promoting apoptosis via the Caspase cascade in LASBC cells.